Kukje Pharma Co., Ltd. (KRX:002720)
South Korea · Delayed Price · Currency is KRW 3,505.00
-70.00 (-1.96%)
Jun 4, 2026, 3:30 PM KST
Kukje Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 177,972 | 175,496 | 156,463 | 135,373 | 126,583 | 119,746 |
Other Revenue | - | -0 | -0 | -0 | -0 | -0 |
| 177,972 | 175,496 | 156,463 | 135,373 | 126,583 | 119,746 | |
Revenue Growth (YoY) | 10.93% | 12.16% | 15.58% | 6.94% | 5.71% | -8.17% |
Cost of Revenue | 82,892 | 81,851 | 73,968 | 68,148 | 63,329 | 65,275 |
Gross Profit | 95,080 | 93,645 | 82,495 | 67,225 | 63,254 | 54,470 |
Selling, General & Admin | 85,011 | 83,587 | 72,895 | 66,699 | 56,119 | 53,538 |
Research & Development | 3,928 | 3,663 | 1,811 | 2,646 | 1,967 | 2,772 |
Amortization of Goodwill & Intangibles | 11.35 | 11.35 | 19.91 | 199.15 | 233.84 | 227.46 |
Operating Expenses | 89,230 | 87,460 | 75,793 | 69,214 | 57,982 | 56,146 |
Operating Income | 5,850 | 6,185 | 6,702 | -1,989 | 5,273 | -1,676 |
Interest Expense | -851.58 | -908.41 | -1,206 | -1,440 | -1,000 | -696.43 |
Interest & Investment Income | 454.6 | 480.66 | 428.67 | 394.02 | 230.88 | 114.3 |
Earnings From Equity Investments | - | - | - | - | 23.21 | -72.91 |
Currency Exchange Gain (Loss) | 524.25 | 34.39 | 303.91 | 163.51 | 450.12 | 589.96 |
Other Non Operating Income (Expenses) | 1,027 | 843.44 | 492.72 | -2,254 | 270.73 | 627.72 |
EBT Excluding Unusual Items | 7,005 | 6,635 | 6,721 | -5,126 | 5,247 | -1,113 |
Gain (Loss) on Sale of Investments | 9.25 | 9.38 | 0.59 | 22.11 | - | - |
Gain (Loss) on Sale of Assets | 39.28 | 15.5 | 114.27 | 290.39 | 13.93 | 31.51 |
Asset Writedown | -221.96 | -216.38 | -226.64 | -1,867 | -515.82 | -28.5 |
Pretax Income | 6,831 | 6,443 | 6,609 | -6,681 | 4,745 | -1,110 |
Income Tax Expense | 839.88 | 738.54 | 1,403 | 1,734 | 1,202 | 445.53 |
Earnings From Continuing Operations | 5,991 | 5,705 | 5,206 | -8,415 | 3,543 | -1,556 |
Minority Interest in Earnings | 0.96 | -7.25 | -0.9 | -0.3 | 14.56 | -3.34 |
Net Income | 5,992 | 5,698 | 5,205 | -8,415 | 3,557 | -1,559 |
Net Income to Common | 5,992 | 5,698 | 5,205 | -8,415 | 3,557 | -1,559 |
Net Income Growth | 39.04% | 9.46% | - | - | - | - |
Shares Outstanding (Basic) | 21 | 20 | 20 | 20 | 20 | 20 |
Shares Outstanding (Diluted) | 21 | 20 | 20 | 20 | 20 | 20 |
Shares Change (YoY) | 1.09% | 0.25% | 0.39% | -0.03% | -0.03% | -0.03% |
EPS (Basic) | 291.49 | 279.51 | 256.00 | -415.49 | 175.58 | -76.93 |
EPS (Diluted) | 291.49 | 279.51 | 256.00 | -415.49 | 175.58 | -77.14 |
EPS Growth | 37.54% | 9.18% | - | - | - | - |
Free Cash Flow | -932.07 | 2,216 | 1,029 | 2,529 | 5,245 | 7,705 |
Free Cash Flow Per Share | -45.34 | 108.73 | 50.60 | 124.88 | 258.88 | 380.18 |
Gross Margin | 53.42% | 53.36% | 52.73% | 49.66% | 49.97% | 45.49% |
Operating Margin | 3.29% | 3.52% | 4.28% | -1.47% | 4.17% | -1.40% |
Profit Margin | 3.37% | 3.25% | 3.33% | -6.22% | 2.81% | -1.30% |
Free Cash Flow Margin | -0.52% | 1.26% | 0.66% | 1.87% | 4.14% | 6.43% |
EBITDA | 9,129 | 9,411 | 9,904 | 2,215 | 9,760 | 2,743 |
EBITDA Margin | 5.13% | 5.36% | 6.33% | 1.64% | 7.71% | 2.29% |
D&A For EBITDA | 3,279 | 3,226 | 3,203 | 4,204 | 4,488 | 4,419 |
EBIT | 5,850 | 6,185 | 6,702 | -1,989 | 5,273 | -1,676 |
EBIT Margin | 3.29% | 3.52% | 4.28% | -1.47% | 4.17% | -1.40% |
Effective Tax Rate | 12.29% | 11.46% | 21.23% | - | 25.34% | - |
Advertising Expenses | - | 3,324 | 3,692 | 6,015 | 7,504 | 7,250 |